Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

NCT07272434 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

25000

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
BIOLOGICAL: Placebo (Saline solution)

Sponsor

MAXVAX Biotechnology Limited Liability Company

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]